Your browser doesn't support javascript.
loading
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg, Yaacov; Deschênes, Georges; Groothoff, Jaap W; Hulton, Sally-Anne; Magen, Daniella; Harambat, Jérôme; Van't Hoff, William G; Lorch, Ulrike; Milliner, Dawn S; Lieske, John C; Haslett, Patrick; Garg, Pushkal P; Vaishnaw, Akshay K; Talamudupula, Sandeep; Lu, Jiandong; Habtemariam, Bahru A; Erbe, David V; McGregor, Tracy L; Cochat, Pierre.
Afiliación
  • Frishberg Y; Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Deschênes G; Department of Pediatric Nephrology, Hôpital Robert Debré, Paris, France.
  • Groothoff JW; Department of Pediatric Nephrology, University of Amsterdam, Amsterdam, The Netherlands.
  • Hulton SA; Department of Nephrology, Birmingham Women's and Children's Hospital, Birmingham, United Kingdom.
  • Magen D; Pediatric Nephrology Institute, Ruth Children's Hospital, Haifa, Israel.
  • Harambat J; Pediatric Nephrology Unit, Bordeaux University Hospital, Bordeaux, France.
  • Van't Hoff WG; Department of Paediatric Nephrology, Great Ormond Street Hospital, London, United Kingdom.
  • Lorch U; Richmond Pharmacology Ltd., London, United Kingdom.
  • Milliner DS; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
  • Lieske JC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
  • Haslett P; Alnylam Pharmaceuticals, Cambridge, Massachusetts.
  • Garg PP; Alnylam Pharmaceuticals, Cambridge, Massachusetts.
  • Vaishnaw AK; Alnylam Pharmaceuticals, Cambridge, Massachusetts.
  • Talamudupula S; Alnylam Pharmaceuticals, Cambridge, Massachusetts.
  • Lu J; Alnylam Pharmaceuticals, Cambridge, Massachusetts.
  • Habtemariam BA; Alnylam Pharmaceuticals, Cambridge, Massachusetts.
  • Erbe DV; Alnylam Pharmaceuticals, Cambridge, Massachusetts.
  • McGregor TL; Alnylam Pharmaceuticals, Cambridge, Massachusetts.
  • Cochat P; Center for Rare Renal Diseases and Institut National de la Santé et de la Recherche Médicale Pediatric Clinical Investigation Center, Hospices Civils de Lyon, Lyon, France.
Clin J Am Soc Nephrol ; 16(7): 1025-1036, 2021 07.
Article en En | MEDLINE | ID: mdl-33985991
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oxalatos / Fármacos Renales / Hiperoxaluria Primaria / ARN Interferente Pequeño Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Clin J Am Soc Nephrol Asunto de la revista: NEFROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Israel
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oxalatos / Fármacos Renales / Hiperoxaluria Primaria / ARN Interferente Pequeño Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Clin J Am Soc Nephrol Asunto de la revista: NEFROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Israel